Table 3: Lab results and clinical
assessments [Revised PsAACTH13 DATA 5-4-15, table 2].
|
Subject |
Week |
CDAI
[PsAACTH13
CDAI DATA (2)] |
Tender
joint count |
Swollen
joint count |
VAS
pain measurement [Revised
PsAACTH13 DATA 5-4-15, table 1] |
Cortisol
(Pre/Post Acthar Gelb), mcg/dL |
CRP,
mg/dLa |
ESR,
mm/hra |
|
2 |
0 |
47 |
18 |
12 |
8 |
18.6/41.7 |
- |
12 |
|
12 |
27 |
15 |
7 |
5 |
11.5/46.7 |
1.39 |
19 |
|
|
24 |
11 |
5 |
3 |
2 |
12.5/41.9 |
0.66 |
1 |
|
|
5 |
0 |
42 |
20 |
13 |
8 |
8.6/33.3 |
- |
24 |
|
12 |
2 |
0 |
1 |
0 |
12.4/33.8 |
0.88 |
23 |
|
|
24 |
6 |
3 |
2 |
2 |
13.8/32.7 |
0.45 |
21 |
|
|
6 |
0 |
50 |
24 |
16 |
8 |
6.4/28.4 |
< 0.10 |
6 |
|
12 |
2 |
0 |
1 |
0 |
5.2/23.7 |
< 0.10 |
4 |
|
|
24 |
5 |
1 |
2 |
0 |
3.7/28.2 |
< 0.10 |
3 |
|
|
9 |
0 |
47 |
20 |
17 |
10 |
15.7/18.1 |
0.21 |
10 |
|
12 |
4 |
2 |
1 |
0 |
7.3/28.3 |
1.91 |
14 |
|
|
24 |
5 |
2 |
1 |
0 |
18.4/29.7 |
0.39 |
10 |
|
|
10 |
0 |
44 |
18 |
18 |
7 |
12.7/25.5 |
0.18 |
18 |
|
12 |
0 |
0 |
0 |
0 |
14.2/33.0 |
0.41 |
15 |
|
|
24 |
0 |
0 |
0 |
0 |
11.2/35.4 |
0.41 |
15 |
|
|
12 |
0 |
48 |
19 |
10 |
8 |
7.5/25.5 |
< 0.32 |
5 |
|
12 |
4 |
3 |
0 |
3 |
7.6/27.2 |
4.81 |
20 |
|
|
24 |
- |
- |
- |
- |
- |
- |
- |
|
|
13 |
0 |
33 |
12 |
8 |
9 |
15.9/31.6 |
4.20 |
92 |
|
12 |
0 |
0 |
0 |
0 |
7.2/40.0 |
0.16 |
10 |
|
|
24 |
0 |
0 |
0 |
0 |
9.4/2.7 |
0.23 |
9 |
|
|
14 |
0 |
41 |
19 |
10 |
7 |
2.6/11.8 |
< 0.10 |
3 |
|
12 |
2 |
1 |
0 |
1 |
7.1/26.1 |
< 0.10 |
0 |
|
|
24 |
3 |
0 |
0 |
1 |
18.5/28.7 |
1.31 |
15 |
aInitial ESR and CRP were conducted at screening, not Week
0.
bCortisol levels were obtained prior to and 1 hour after
administration of Acthar Gel.
CDAI: Clinical Disease Activity Index; CRP: C-Reactive Protein; ESR: Erythrocyte Sedimentation Rate; VAS:
Visual Analog Scale.